Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 2, 2008, Pages 176-179

  Yasar, Umit ^a   Babaoglu, Melih O ^a   Bozkurt, Atila ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; LOSARTAN; LOSARTAN POTASSIUM; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ADULT; ARTICLE; CYP2C9 GENE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG OXIDATION; ENZYME ACTIVITY; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MDR1 GENE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TURKEY (BIRD);

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TISSUE DISTRIBUTION;

EID: 47649110030     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00283.x     Document Type: Article

References (27)

1. Timmermans PBMWM. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999 22 : 147 53.
2. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001 29 : 1051 6.
3. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F et al. Pharmacokinetics of losartan and its metabolite E3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002 71 : 89 98.
4. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995 58 : 641 9.
5. Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003 59 : 589 92.
6. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther 2004 76 : 113 8.
7. Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004 60 : 337 42.
8. Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002 54 : 183 5.
9. Xie HJ, Yasar U, Sandberg M, Rane A. Paeoniae radix, a traditional chinese medicine, and CYP2C9 activity. J Clin Pharm Ther 2002 27 : 229 30.
10. Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O et al. Inhibitory effect of 5-fluorouracil on cytochrome P4502C9 activity in cancer patients. Basic Clin Pharmacol Toxicol 2006 98 : 197 200.
11. Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A. Tamoxifen inhibits cytochrome P4502C9 activity in breast cancer patients. J Chemother 2006 18 : 421 4.
12. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther 2005 77 : 1 16.
13. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004 14 : 527 37.
14. Lee CR, Goldstein JA, Pieper JA. Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002 12 : 251 63.
15. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. Clin Appl Thromb Hemost 2004 10 : 149 54.
16. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004 75 : 13 33.
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000 97 : 3473 8.
18. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002 71 : 297 303.
19. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: Functional relevance to pharmacokinetics of digoxin. Pharm Res 2002 19 : 1581 5.
20. Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I et al. Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 2005 78 : 619 26.
21. Soldner A, Benet LZ, Mutschler E, Christians U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 2000 129 : 1235 43.
22. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003 13 : 259 63.
23. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005 78 : 260 77.
24. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002 13 : 1847 54.
25. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003 124 : 26 33.
26. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003 348 : 1442 8.
27. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002 359 : 30 6.